Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

Jul 18 2018

• By Emily Hayes

Heart disease in a person with obesity, conceptual image. 3D illustration showing increased weight male with obese heart

Related Content

Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

Sep 01 2009

Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH

Jul 11 2017

Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales

Oct 14 2016

Third Time's The Charm? Orexigen Terminates CONVENE

Apr 14 2016

Novo's Saxenda bags FDA approval for weight management

Dec 24 2014

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

May 03 2018

Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect

Aug 29 2017

Related Companies

Eisai Co., Ltd.

Arena Pharmaceuticals, Inc.

Vivus, Inc.

Orexigen Therapeutics, Inc.

Novo Nordisk A/S

Johnson & Johnson

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Clinical Trials FDA Research & Development Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window